Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Consort Medical PLC - Restated

23 Jan 2020 13:53

RNS Number : 7676A
Peel Hunt LLP
23 January 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

Form 8.5 (EPT/RI) - Consort Medical PLC announcement released on 23/01/2020 at 13:22 under RNS No 7655A has been amended.

 

Amendments are identified with an asterisk (*).

 

The full amended text is shown below.

 

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Consort Medical Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Recipharm Holdings Limited

(d) Date dealing undertaken:

22 January 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

5,000,000*

1,010.00 GBx

1,000.00 GBx

Ordinary Shares

Sell

5,000,000*

1,009.63 GBx

1,009.63 GBx

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

 

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

23 January 2020

 

Contact name:

Kathleen Lloyd

Telephone number:

0207 418 8911

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERSEDFDDESSEIF
Date   Source Headline
1st Nov 20179:35 amRNSDirector/PDMR Shareholding
1st Nov 20179:04 amRNSTotal Voting Rights
16th Oct 20179:42 amRNSBlock listing Interim Review
11th Oct 20172:10 pmRNSDirector/PDMR Shareholding
11th Oct 201711:38 amRNSHolding(s) in Company
2nd Oct 201710:03 amRNSTotal Voting Rights
11th Sep 20175:15 pmRNSDirector/PDMR Shareholding
7th Sep 20171:56 pmRNSDirector/PDMR Shareholding
6th Sep 20174:35 pmRNSResult of AGM
1st Sep 20172:47 pmRNSDirector Declaration
10th Aug 20178:38 amRNSDirector/PDMR Shareholding
1st Aug 20177:00 amRNSTotal Voting Rights
28th Jul 20173:48 pmRNSPosting of Annual Financial Report and AGM Notice
26th Jul 20179:22 amRNSDirector/PDMR Shareholding
20th Jul 20178:07 amRNSAdditional Listing
11th Jul 20178:53 amRNSDirector/PDMR Shareholding
21st Jun 201712:10 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
21st Jun 201712:09 pmRNSDirector/PDMR Shareholding
15th Jun 20177:00 amRNSFull year results
5th Jun 201710:09 amRNSDirector Declaration
8th May 20177:00 amRNSNotice of Results
2nd May 201711:10 amRNSTotal Voting Rights
27th Apr 201711:51 amRNSResult of General Meeting
18th Apr 20179:36 amRNSBlock listing Interim Review
3rd Apr 20179:49 amRNSNotice of GM
1st Mar 20179:22 amRNSTotal Voting Rights
30th Jan 201712:44 pmRNSHolding(s) in Company
26th Jan 20172:59 pmRNSHolding(s) in Company
23rd Jan 20177:00 amRNSParticipation in equity raise for Atlas Genetics
3rd Jan 20177:00 amRNSVoke® (DEV200) update
15th Dec 20169:45 amRNSHolding(s) in Company
14th Dec 201610:35 amRNSHolding(s) in Company
14th Dec 20167:00 amRNSDirectorate Change
9th Dec 20163:18 pmRNSDirector/PDMR Shareholding
6th Dec 20167:00 amRNSInterim Results
2nd Dec 20169:25 amRNSHolding(s) in Company
1st Dec 20169:43 amRNSTotal Voting Rights
25th Nov 20167:00 amRNSCFO Appointment
8th Nov 20161:24 pmRNSDirector/PDMR Shareholding
1st Nov 201610:15 amRNSTotal Voting Rights
31st Oct 20163:32 pmRNSDirector/PDMR Shareholding
31st Oct 20161:00 pmRNSNotice of Results
27th Oct 20167:00 amRNSCIMZIA® AutoClicks® prefilled pen launched in UK
14th Oct 201610:02 amRNSBlock listing Interim Review
14th Oct 20167:00 amRNSAnnouncement of master development agreement
11th Oct 201612:03 pmRNSDirector/PDMR Shareholding
3rd Oct 20169:00 amRNSTotal Voting Rights
19th Sep 20169:47 amRNSBespak Technology in UCB PrefilledPen EMA Approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.